Data science company IXICO extends contract with biopharmaceutical firm - Pharma Business review

The original contract in Alzheimer's disease was announced on 5 July 2017 and this change order reflects an extension of the contract term from September 2020 to May 2021 and the addition of new clinical sites. Change orders often occur as part of the normal course of multi-year contracts, as the scope of services that IXICO provides can be expanded or extended during the term of a clinical trial. IXICO CEO Giulio Cerroni said: "We are delighted to announce a further extension and expansion of this project. This change order and increase in contract value, demonstrates how closely we work with our biopharmaceutical clients to expand the services we provide to their clinical development programmes." IXICO is dedicated to delivering insights in neuroscience.